JP2009538607A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538607A5
JP2009538607A5 JP2009512510A JP2009512510A JP2009538607A5 JP 2009538607 A5 JP2009538607 A5 JP 2009538607A5 JP 2009512510 A JP2009512510 A JP 2009512510A JP 2009512510 A JP2009512510 A JP 2009512510A JP 2009538607 A5 JP2009538607 A5 JP 2009538607A5
Authority
JP
Japan
Prior art keywords
responder
ccl5
patient
immunotherapy
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538607A (ja
Filing date
Publication date
Priority claimed from GB0610949A external-priority patent/GB0610949D0/en
Priority claimed from GB0700761A external-priority patent/GB0700761D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/004915 external-priority patent/WO2007140958A2/en
Publication of JP2009538607A publication Critical patent/JP2009538607A/ja
Publication of JP2009538607A5 publication Critical patent/JP2009538607A5/ja
Pending legal-status Critical Current

Links

JP2009512510A 2006-06-02 2007-05-31 患者が免疫療法に対する応答者であるかどうかを同定する方法 Pending JP2009538607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0610949A GB0610949D0 (en) 2006-06-02 2006-06-02 Method
GB0700761A GB0700761D0 (en) 2007-01-15 2007-01-15 Method
PCT/EP2007/004915 WO2007140958A2 (en) 2006-06-02 2007-05-31 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (2)

Publication Number Publication Date
JP2009538607A JP2009538607A (ja) 2009-11-12
JP2009538607A5 true JP2009538607A5 (enExample) 2010-07-08

Family

ID=38801855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512510A Pending JP2009538607A (ja) 2006-06-02 2007-05-31 患者が免疫療法に対する応答者であるかどうかを同定する方法

Country Status (15)

Country Link
US (1) US20100021424A1 (enExample)
EP (23) EP2390357A1 (enExample)
JP (1) JP2009538607A (enExample)
KR (1) KR20090017655A (enExample)
AR (1) AR061136A1 (enExample)
AU (1) AU2007256383B2 (enExample)
BR (1) BRPI0712497A2 (enExample)
CA (1) CA2653949A1 (enExample)
CL (1) CL2007001571A1 (enExample)
EA (1) EA200802242A1 (enExample)
ES (1) ES2539042T3 (enExample)
MX (1) MX2008015372A (enExample)
PE (1) PE20080742A1 (enExample)
TW (1) TW200817680A (enExample)
WO (1) WO2007140958A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
JP5706913B2 (ja) * 2009-12-16 2015-04-22 日立化成株式会社 攻撃的及び防御的免疫マーカーのｅｘｖｉｖｏ誘導により宿主免疫機能を特徴付けるための方法
EP2380991A1 (en) 2010-04-20 2011-10-26 Universitätsklinikum Hamburg-Eppendorf Method of determining the metastatic potential of a tumor
EA201390370A1 (ru) * 2010-09-15 2013-07-30 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест для определения онкологического заболевания
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
WO2014009535A2 (en) * 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
AU2015283869B2 (en) * 2014-07-03 2020-04-02 University Of Virginia Patent Foundation Systems and methods for identifying and profiling muscle patterns
US20170298443A1 (en) * 2014-09-25 2017-10-19 Moffitt Genetics Corporation Prognostic tumor biomarkers
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
JP6489900B2 (ja) * 2015-03-30 2019-03-27 株式会社ジャパンディスプレイ 入力装置及び表示装置
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
WO2017011623A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7457642B2 (ja) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
GB201908565D0 (en) * 2019-06-14 2019-07-31 Cray Innovation Ab Method of stratifying subjects into sub-groups for therapeutic treatment
CN114540504B (zh) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 用于预测肺鳞癌患者免疫疗效的标志物组及系统

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
EP1104306B1 (en) 1998-08-10 2006-01-11 Antigenics Inc. Compositions of cpg and saponin adjuvants and methods of use thereof
AU780109B2 (en) 1999-01-29 2005-03-03 Corixa Corporation HER-2/neu fusion proteins
TR200102781T2 (tr) 1999-03-11 2002-01-21 Smithkline Beecham Biologicals S. A. Yeni bileşikler
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
CN1254541C (zh) 2000-02-23 2006-05-03 史密丝克莱恩比彻姆生物有限公司 新化合物
AUPR077900A0 (en) * 2000-10-13 2000-11-09 Tvw Telethon Institute For Child Health Research Immunodiagnosis
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
WO2002076469A1 (en) * 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
AU2002360525A1 (en) * 2001-12-06 2003-06-23 University Of Florida Targeting leukemia cells
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
DK1511768T3 (da) 2002-06-11 2007-08-20 Glaxosmithkline Biolog Sa Immunogene sammensætninger
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
CA2516182A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Expression profiles for breast cancer and methods of use
EP1651772A1 (en) * 2003-03-07 2006-05-03 Arcturus Bioscience, Inc. Breast cancer signatures
WO2004081564A1 (en) 2003-03-14 2004-09-23 Peter Maccallum Cancer Institute Expression profiling of tumours
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
CA2530184C (en) * 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
EP1677733A4 (en) 2003-10-03 2007-09-19 Bayer Pharmaceuticals Corp GENE EXPRESSION PROFILES AND METHOD OF USE
WO2005044999A2 (en) * 2003-11-05 2005-05-19 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005054496A1 (ja) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. 細胞動態の検査方法
WO2005059543A1 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963)
KR20070003883A (ko) * 2004-02-09 2007-01-05 후소 야쿠힝 고교 가부시끼가이샤 핵산 검출방법 및 그 이용
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
DE602005023488D1 (de) * 2004-06-17 2010-10-21 Mannkind Corp Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20060110371A1 (en) * 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
WO2006060653A2 (en) 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006073982A2 (en) * 2004-12-30 2006-07-13 Regents Of The University Of California Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
KR20080004551A (ko) 2005-04-01 2008-01-09 엔씨씨 테크놀로지 벤쳐스 피티이 리미티드 유방암 분류에 관한 재료 및 방법
EP2083088A3 (en) * 2005-04-07 2009-10-14 Novartis Vaccines and Diagnostics, Inc. Cancer-related genes
US20090203639A1 (en) * 2005-04-15 2009-08-13 Oncomethylome Sciences, Inc. Methylation Markers for Diagnoses and Treatment of Cancers
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
EP1904845A4 (en) * 2005-07-07 2009-11-25 David E Kohne IMPROVED RESULTS AND APPLICATION OF COMPARISON EXAMPLES OF PROTEIN EXPRESSIONS
CN101283275A (zh) * 2005-10-11 2008-10-08 默克专利有限公司 趋化因子表达的依赖egfr的调控和对肿瘤的诊断和治疗的影响及其副作用
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Similar Documents

Publication Publication Date Title
Bonne et al. Salivary biomarker development using genomic, proteomic and metabolomic approaches
Payne et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma
JP2020028300A5 (enExample)
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
Udovicich et al. 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends
EA201070863A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
JP2013066474A5 (enExample)
WO2011103236A3 (en) Personalized tumor biomarkers
JP2016500110A5 (enExample)
WO2012047899A3 (en) Novel dna hypermethylation diagnostic biomarkers for colorectal cancer
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
WO2010027903A3 (en) Lung cancer diagnosis
MX2013006669A (es) Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
ATE554389T1 (de) Apex als marker für lungenkrebs
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer